EU regulators move up Pfizer vaccine assessment to Dec. 21

BERLIN » Facing strong pressure from Germany and other European Union nations, the bloc’s medicines agency on Tuesday moved up a meeting to assess the Pfizer-BioNTech coronavirus vaccine to Dec. 21, likely bringing vaccinations a step closer for millions of EU citizens.

The agency said it made the decision after receiving additional data from the vaccine makers. The announcement came after Germany’s health minister and others had publicly demanded that the agency move quicker than its previously planned Dec. 29 meeting at which it was to discuss approving the vaccine.

The vaccine is already being given daily to thousands of people in Britain, Canada and the United States, galling some Europeans who note that BioNTech is a Germany company.